Skip to main content

Bright Peak Therapeutics Inc. and Ajinomoto Co., Inc. Enter into a Research Collaboration and License Agreement to Create Novel Immunocytokines

SAN DIEGO and TOKYO, March 25, 2021 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics Inc., a biotechnology company developing next generation immunotherapies for cancer and autoimmune disease, and Ajinomoto Co., Inc. ("Ajinomoto Co."), a leading technology provider for biopharmaceuticals and the owner of Ajinomoto Bio-Pharma Services offering pharmaceutical contract development and manufacturing services, today announced a research collaboration and exclusive license agreement to incorporate AJICAP®,  Ajinomoto Co.’s proprietary site-specific bioconjugation technology, for the development of Bright Peak Immunocytokines. Read More

from Financial Post https://ift.tt/3lOuVyU
Labels:

Comments

Post a Comment

Popular posts from this blog

With Trump’s WeChat ban approaching, here are several alternatives

Our mission to help you navigate the new normal is fueled by subscribers. To enjoy unlimited access to our journalism,  subscribe today . WeChat, China’s most popular app, faces an imminent ban in the U.S. , leaving many of its users in a bind. The White House said Friday it would prohibit WeChat , owned by Beijing-based Tencent, from appearing in U.S. app stores starting Sunday at midnight.  Though WeChat has a comparatively minor U.S. presence, it remains a major conduit for communications between Chinese nationals living abroad and their friends and family back home . The app has an average of 19 million million daily active users in the U.S. versus more than a billion worldwide.  WeChat, called Weixin in China, is effectively the operating system for people’s digital lives in China. They use it to pay for services, hail cabs, go shopping, read news, chat, and more. For people seeking to bridge the digital divide between the U.S. and China, WeChat is not easily re...
Post a Comment
Read more